Drug Shortage Alert 7/19/2012 Intravenous Sodium Bicarbonate
... pH is maintained at >7.5. Sodium bicarbonate-induced serum alkalemia may reduce the risk of severe central nervous system toxicity by shifting salicylates from tissue to the blood. Acetazolamide should not be administered as an alternative as the potential resulting metabolic acidosis can increase s ...
... pH is maintained at >7.5. Sodium bicarbonate-induced serum alkalemia may reduce the risk of severe central nervous system toxicity by shifting salicylates from tissue to the blood. Acetazolamide should not be administered as an alternative as the potential resulting metabolic acidosis can increase s ...
Spleen Therapy in Practice
... for example, to illness, work or worry, it releases more blood into the body. We now know that the spleen is also responsible for important functions in the body’s immune system. Whereas immature T lymphocytes from the bone marrow are matured into helper, suppressor and killer cells in the thymus, c ...
... for example, to illness, work or worry, it releases more blood into the body. We now know that the spleen is also responsible for important functions in the body’s immune system. Whereas immature T lymphocytes from the bone marrow are matured into helper, suppressor and killer cells in the thymus, c ...
Pharmacological Treatment for Stage C HFrEF (cont.)
... b. whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; c. whose renal function is worsening with therapy; d. who require parenteral vasoactive agents; or e. who may need consideration for MCS or transplantation. ...
... b. whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; c. whose renal function is worsening with therapy; d. who require parenteral vasoactive agents; or e. who may need consideration for MCS or transplantation. ...
Gastro-oesophageal reflux disease and dyspepsia in adults
... Dyspepsia describes a range of symptoms arising from the upper gastrointestinal (GI) tract, but it has no universally accepted definition. The British Society of Gastroenterology (BSG) defines dyspepsia as a group of symptoms that alert doctors to consider disease of the upper GI tract, and states t ...
... Dyspepsia describes a range of symptoms arising from the upper gastrointestinal (GI) tract, but it has no universally accepted definition. The British Society of Gastroenterology (BSG) defines dyspepsia as a group of symptoms that alert doctors to consider disease of the upper GI tract, and states t ...
The effectiveness of highly active antiretroviral therapy in HIV
... comply with this problem include the use of a longer observation period, a larger study population, and/or collapsing the data on morbidity and mortality into one clinical outcome measure, often given the term: “clinical progression”. Especially in clinical trials evaluating new or existing treatmen ...
... comply with this problem include the use of a longer observation period, a larger study population, and/or collapsing the data on morbidity and mortality into one clinical outcome measure, often given the term: “clinical progression”. Especially in clinical trials evaluating new or existing treatmen ...
Treatment for LTBI in contacts of MDR-TB patients - CAP-TB
... Of the 119 contacts with MDR LTBI, 104 (87%) initiated treatment and 15 (13%) refused treatment or discontinued treatment within 2 weeks. The median age of those who began treatment was 24 years (range 1–62) (Table 2). The 15 contacts who refused were older (median age 32 years), but were otherwise ...
... Of the 119 contacts with MDR LTBI, 104 (87%) initiated treatment and 15 (13%) refused treatment or discontinued treatment within 2 weeks. The median age of those who began treatment was 24 years (range 1–62) (Table 2). The 15 contacts who refused were older (median age 32 years), but were otherwise ...
Appropriate use of intravenously administered immunoglobulin
... evidence. A comprehensive review of the evidence supporting the use of IGIV in specific indications is beyond the scope of this document, but was reviewed in detail in its preparation. The entire summary of evidence and detailed recommendations regarding the use of IGIV will be published elsewhere a ...
... evidence. A comprehensive review of the evidence supporting the use of IGIV in specific indications is beyond the scope of this document, but was reviewed in detail in its preparation. The entire summary of evidence and detailed recommendations regarding the use of IGIV will be published elsewhere a ...
Chapter 308. Cirrhosis and Its Complications
... therapy, which is effective at viral suppression, as evidenced by reducing aminotransferase levels and HBV DNA levels, and improving histology by reducing inflammation and fibrosis. Several clinical trials and case series have demonstrated that patients with decompensated liver disease can become co ...
... therapy, which is effective at viral suppression, as evidenced by reducing aminotransferase levels and HBV DNA levels, and improving histology by reducing inflammation and fibrosis. Several clinical trials and case series have demonstrated that patients with decompensated liver disease can become co ...
Application of Prodrugs to Inflammatory Diseases of the
... In order to achieve an effective colonic delivery, a drug needs to be protected from absorption and/or the environment of upper GI tract and then rapidly released into the proximal colon, which is the optimalsite for colon-targeted delivery of the drug. Colonic drug delivery through colon-specific p ...
... In order to achieve an effective colonic delivery, a drug needs to be protected from absorption and/or the environment of upper GI tract and then rapidly released into the proximal colon, which is the optimalsite for colon-targeted delivery of the drug. Colonic drug delivery through colon-specific p ...
PRODUCT MONOGRAPH POLLINEX®-R Modified Ragweed Pollen
... POLLINEX-R is not expected to completely eliminate the various allergic symptoms but should reduce their severity. POLLINEX-R may also be expected to reduce a patient’s dependence on symptomatic medication (antihistamines and other cough/cold over-the-counter products) taken during the ragweed seaso ...
... POLLINEX-R is not expected to completely eliminate the various allergic symptoms but should reduce their severity. POLLINEX-R may also be expected to reduce a patient’s dependence on symptomatic medication (antihistamines and other cough/cold over-the-counter products) taken during the ragweed seaso ...
Rhinitis - ENT Lectures
... function should recover within 7-21 days after sympathomimetics are discontinued. Topical nasal steroid spray may ease the transition from the sympathomimetic agents, and some suggest allowing the patient to continue using the offending agent at night for a few days or weaning 1 nostril at a time. N ...
... function should recover within 7-21 days after sympathomimetics are discontinued. Topical nasal steroid spray may ease the transition from the sympathomimetic agents, and some suggest allowing the patient to continue using the offending agent at night for a few days or weaning 1 nostril at a time. N ...
Desmopressin Acetate Injection, USP
... desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses ...
... desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses ...
New York Neck Injury Medical Treatment Guidelines
... TREATMENT TIME FRAMES Treatment time frames for specific interventions commence once treatments have been initiated, not on the date of injury. Obviously, duration may be impacted by disease process and severity, patient compliance, as well as availability of services. Clinical judgment may substant ...
... TREATMENT TIME FRAMES Treatment time frames for specific interventions commence once treatments have been initiated, not on the date of injury. Obviously, duration may be impacted by disease process and severity, patient compliance, as well as availability of services. Clinical judgment may substant ...
Restless legs syndrome
... Levodopa has the longest history of use in RLS. It has a short halflife (1-2 hours) and can therefore be associated with rebound symptoms later in the night. It also has a high rate of augmentation over time (60% — see below) and is generally avoided in patients with moderate to severe symptoms.33 L ...
... Levodopa has the longest history of use in RLS. It has a short halflife (1-2 hours) and can therefore be associated with rebound symptoms later in the night. It also has a high rate of augmentation over time (60% — see below) and is generally avoided in patients with moderate to severe symptoms.33 L ...
Ch17: Bleeding and Clotting Disorders
... clotting mechanisms have been altered by inherited or acquired diseases. This provides an opportunity for the dentist who is trained in the recognition of oral and systemic signs of altered hemostasis to assist in the diagnosis of the underlying condition. A number of dental procedures result in the ...
... clotting mechanisms have been altered by inherited or acquired diseases. This provides an opportunity for the dentist who is trained in the recognition of oral and systemic signs of altered hemostasis to assist in the diagnosis of the underlying condition. A number of dental procedures result in the ...
Recommendations for the Management of Gout and Hyperuricemia
... o’clock in the morning he is awakened by a severe pain in the great toe; more rarely in the heel, ankle or instep. This pain is like that of a dislocation. ... Then it is a violent stretching and tearing of the ligaments. … now it is a gnawing pain and now a pressure and tightening. … He cannot bear ...
... o’clock in the morning he is awakened by a severe pain in the great toe; more rarely in the heel, ankle or instep. This pain is like that of a dislocation. ... Then it is a violent stretching and tearing of the ligaments. … now it is a gnawing pain and now a pressure and tightening. … He cannot bear ...
duodopa_uetmis dec 2014_eng translation
... Few quality evidence was identified. However, the results of the studies included suggest that continuous LCIG could be effective in reducing the daily duration of the periods when the symptoms are not controlled by medication (off-periods) and the motor complications associated with this drug. The ...
... Few quality evidence was identified. However, the results of the studies included suggest that continuous LCIG could be effective in reducing the daily duration of the periods when the symptoms are not controlled by medication (off-periods) and the motor complications associated with this drug. The ...
rch - Therapeutic Goods Administration
... dipropionate (or equivalent) plus long-acting beta2-agonist. Oral corticosteroid (22%), theophylline (27%) and anti-leukotriene (35%) maintenance therapies were allowed. In the treatment phase concomitant asthma therapy was not changed. The rate of asthma exacerbations requiring treatment with syste ...
... dipropionate (or equivalent) plus long-acting beta2-agonist. Oral corticosteroid (22%), theophylline (27%) and anti-leukotriene (35%) maintenance therapies were allowed. In the treatment phase concomitant asthma therapy was not changed. The rate of asthma exacerbations requiring treatment with syste ...
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES
... two lesions were detected in at least one of the two sequences: 128 were seen only on fastFLAIR, 17 only on CSE. 41 lesions were larger on fast-FLAIR, while no lesion was considered larger on CSE. The numbers of periventricular (P = 0.05), cortical/subcortical (P = 0.02) and discrete (P = 0.05) lesi ...
... two lesions were detected in at least one of the two sequences: 128 were seen only on fastFLAIR, 17 only on CSE. 41 lesions were larger on fast-FLAIR, while no lesion was considered larger on CSE. The numbers of periventricular (P = 0.05), cortical/subcortical (P = 0.02) and discrete (P = 0.05) lesi ...
CHRONIC PAIN SYNDROME
... (sympathetically mediated pain) SIP (sympathetically independent pain) Majority of CRPS are associated with SMP but fewer cases are found to be SIP. ...
... (sympathetically mediated pain) SIP (sympathetically independent pain) Majority of CRPS are associated with SMP but fewer cases are found to be SIP. ...
THE CLASSIC A Clinical Staging System for Adult Osteomyelitis
... pathophysiologic component: soft tissue compromise. In medullary osteomyelitis the primary lesion is endosteal. The etiology of the disease is variable but the nidus remains constant: ischemic scar, chronic granulations, and splinter sequestra within the medullary canal. In superficial osteomyelitis ...
... pathophysiologic component: soft tissue compromise. In medullary osteomyelitis the primary lesion is endosteal. The etiology of the disease is variable but the nidus remains constant: ischemic scar, chronic granulations, and splinter sequestra within the medullary canal. In superficial osteomyelitis ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.